Santen Obtains Manufacturing and Marketing Approval in Japan for Rhopressa® Ophthalmic Solution 0.02%, a Treatment for Glaucoma and Ocular Hypertension
We bring you the latest updates from Santen Pharmaceutical News through a simple and fast subscription.
We can deliver your news in your inbox, on your phone or you can read them here on this website on your personal news page.
Unsubscribe at any time without hassle.
Santen Pharmaceutical News's title: Santen Pharmaceutical Co., Ltd | Happiness with Vision (santen.com)